Rolapitant and Rifampin Interaction
Drug interaction information between Rolapitant and Rifampin.
Rolapitant and Rifampin have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Rolapitant and Rifampin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Rifampin significantly lowers the levels of rolapitant in your blood. This makes the medication much less effective at preventing nausea and vomiting.
What To Do
Avoid using this combination if you are taking rifampin on a long-term basis. Your doctor will need to find a different medicine for you.
FDA Label Information
rifampin) Clinical Impact: Co-administration of VARUBI with rifampin can significantly reduce the plasma concentrations of rolapitant and decrease the efficacy of VARUBI [see Clinical Pharmacology (12.3) ] . Strong CYP3A4 Inducers (e.g., rifampin) : significantly reduced plasma concentrations of rolapitant can decrease the efficacy of VARUBI; avoid use of VARUBI in patients who require chronic administration of such drugs.
Rolapitant Also Interacts With
- Pimozide major
- Thioridazine major
- Rosuvastatin minor
- Warfarin minor
- Methotrexate minor
Rifampin Also Interacts With
- Darunavir major
- Bictegravir/Emtricitabine/Tenofovir major
- Glecaprevir/Pibrentasvir major
- Nirmatrelvir/Ritonavir major
- Pitavastatin major
Frequently Asked Questions
Can I take Rolapitant and Rifampin together?
This is a moderate interaction. Avoid using this combination if you are taking rifampin on a long-term basis. Your doctor will need to find a different medicine for you.
How serious is the interaction between Rolapitant and Rifampin?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Rolapitant and Rifampin interact?
Rifampin significantly lowers the levels of rolapitant in your blood. This makes the medication much less effective at preventing nausea and vomiting.
Understanding the Rolapitant and Rifampin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Rolapitant belongs to the NK1 Receptor Antagonist (Antiemetic) class and Rifampin belongs to the Rifamycin Antibiotic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rifampin significantly lowers the levels of rolapitant in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Rolapitant has 9 total documented interactions on file in this dataset, and Rifampin has 137. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid using this combination if you are taking rifampin on a long-term basis. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rolapitant or Rifampin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.